Intra-articular Botulinum Neurotoxin in Knee Osteoarthritis

The Evaluation of Effects of Intra-articular Botulinum Neurotoxin on Pain and Function in Patients with Knee Osteoarthritis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180416039323N1

Enrollment

Registered

2018-07-29

Start date

2018-04-30

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis. Secondary osteoarthritis of other joints

Interventions

Intervention group: Injection of 250 units of botulinum toxin (Dysport), diluted in 5 ml of normal saline, in each knee.

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: age ?50 crepitation or morning stiffness 3 months

Exclusion criteria

Exclusion criteria: Patient dissatisfaction Other articular disease in knee joint Surgical history in the joint Fracture history in bones of knee Corticosteroid knee injection in the last 2 weeks, hyalorunic acid injection or prolotherapy over the past year Any intraarticular injection contraindication Allergy to toxin Severe knee joint effusion

Design outcomes

Primary

Measure	Time frame
Evaluation of pain intensity and functional improvement with Knee Injury and Osteoarthritis Outcome Score questionnaire. Timepoint: evaluation of pain intensity and functional improvement before and 1 month after botulinum toxin injection. Method of measurement: Knee Injury and Osteoarthritis Outcome Score questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahsa Khademi

Artesh University of Medical Sciences

m_khademii@yahoo.com+98 21 8802 8350

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 3, 2026